Catalog No.
RXX00403
Species reactivity
Bacillus anthracis
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Protective antigen, PA, Anthrax toxins translocating protein, PA-83, PA83, Protective antigen PA-20, PA-20, PA20, Protective antigen PA-63, PA-63, PA63, pagA, pag, pXO1-110, BXA0164, GBAA_pXO1_0164
Concentration
1.5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P13423
Applications
ELISA, Neutralization
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA1377
A Nasal Vaccine Displaying Anthrax Antigen on the Surface of Lactiplantibacillus plantarum Induces Protective Mucosal Immunity against Anthrax Toxin., PMID:40443240
Negative Association of Gulf War Illness Symptomatology with Predicted Binding Affinity of Anthrax Vaccine Antigen to Human Leukocyte (HLA) Class II Molecules., PMID:39852867
Electrochemical immunosensor for Bacillus anthracis PA toxin using a polypyrrole-gold nanoparticle/multiwall carbon nanotube sensing platform and cadmium sulphide nanocrystal signal tag., PMID:39851166
Toxin and capsule production by Bacillus cereus biovar anthracis influence pathogenicity in macrophages and animal models., PMID:39715264
Rapid in vitro activity of telavancin against Bacillus anthracis and in vivo protection against inhalation anthrax infection in the rabbit model., PMID:38888319
Visualization of immune pathways that enhance the neutralizing antibody response to vaccines after primary immunization., PMID:38334423
Human Exposure to Naturally Occurring Bacillus anthracis in the Kars Region of Eastern Türkiye., PMID:38257993
Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax., PMID:38115181
One Health Assessment of Bacillus anthracis Incidence and Detection in Anthrax-Endemic Areas of Pakistan., PMID:37894120
Development of a New Cell-Based AP-1 Gene Reporter Potency Assay for Anti-Anthrax Toxin Therapeutics., PMID:37755954
Protective antigen of Bacillus anthracis in combination with TLR4 or TLR5 agonist confers superior protection against lethal challenge in mouse model., PMID:37437686
Feral Swine as Indirect Indicators of Environmental Anthrax Contamination and Potential Mechanical Vectors of Infectious Spores., PMID:37111508
Immunogenicity and Protective Efficacy of Recombinant Protective Antigen Anthrax Vaccine (GC1109) in A/J Mice Model., PMID:37055344
Inhalable vaccine of bacterial culture supernatant extract mediates protection against fatal pulmonary anthrax., PMID:36920800
Recombinant full-length Bacillus Anthracis protective antigen and its 63 kDa form elicits protective response in formulation with addavax., PMID:36713362
Impact of HLA Polymorphism on the Immune Response to Bacillus Anthracis Protective Antigen in Vaccination versus Natural Infection., PMID:36298436
Welder's Anthrax: A Tale of 2 Cases., PMID:36251561
Clinical Features of Patients Hospitalized for All Routes of Anthrax, 1880-2018: A Systematic Review., PMID:36251560
Antitoxin Use in the Prevention and Treatment of Anthrax Disease: A Systematic Review., PMID:36251559
Pre- and Postlicensure Animal Efficacy Studies Comparing Anthrax Antitoxins., PMID:36251555
Systematic Review of Hospital Treatment Outcomes for Naturally Acquired and Bioterrorism-Related Anthrax, 1880-2018., PMID:36251553
New formulation of a recombinant anthrax vaccine stabilised with structurally modified plant viruses., PMID:36160184
Serological responses to Anthrax Vaccine Precipitated (AVP) increase with time interval between booster doses., PMID:36153153
Use of protective antigen of Bacillus anthracis as a model recombinant antigen to evaluate toll-like receptors 2, 3, 4, 7 and 9 agonists in mice using established functional antibody assays, antigen-specific antibody assays and cellular assays., PMID:35773119
Immunological Evidence of Variation in Exposure and Immune Response to Bacillus anthracis in Herbivores of Kruger and Etosha National Parks., PMID:35237267
Production of a Bacillus anthracis Secretome with Suitable Characteristics as Antigen in a Complement Fixation Test., PMID:35207599
Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adults., PMID:35153091
A multipathogen DNA vaccine elicits protective immune responses against two class A bioterrorism agents, anthrax and botulism., PMID:35141866
Mechanism of Action of Monoclonal Antibodies That Block the Activity of the Lethal Toxin of Bacillus Anthracis., PMID:35127153
Using a Syrian (Golden) Hamster Biological Model for the Evaluation of Recombinant Anthrax Vaccines., PMID:34947919
Characterization of the adaptive immune response of donors receiving live anthrax vaccine., PMID:34928976
Development of ELISA based on Bacillus anthracis capsule biosynthesis protein CapA for naturally acquired antibodies against anthrax., PMID:34634075
Liposome-based nanocarriers loaded with anthrax lethal factor and armed with anti-CD19 VHH for effectively inhibiting MAPK pathway in B cells., PMID:34500284
Neutralization of the anthrax toxin by antibody-mediated stapling of its membrane-penetrating loop., PMID:34473089
A novel bicistronic DNA vaccine with enhanced protective immune response against Bacillus anthracis through DNA prime-protein boost vaccination approach., PMID:34298126
Evaluation of the AV7909 Anthrax Vaccine Toxicity in Sprague Dawley Rats Following Three Intramuscular Administrations., PMID:34281421
Insufficient Anthrax Lethal Toxin Neutralization Is Associated with Antibody Subclass and Domain Specificity in the Plasma of Anthrax-Vaccinated Individuals., PMID:34199431
Single-dose combination nanovaccine induces both rapid and durable humoral immunity and toxin neutralizing antibody responses against Bacillus anthracis., PMID:34090702
Construction of a bivalent vaccine against anthrax and smallpox using the attenuated vaccinia virus KVAC103., PMID:33685392
Bacillus anthracis edema toxin inhibits hypoxic pulmonary vasoconstriction via edema factor and cAMP-mediated mechanisms in isolated perfused rat lungs., PMID:33064559
Teixobactin Provides Protection against Inhalation Anthrax in the Rabbit Model., PMID:32971758
A serological survey of Bacillus anthracis reveals widespread exposure to the pathogen in free-range and captive lions in Zimbabwe., PMID:32964687
Vaccine Delivery with a Detoxified Bacterial Toxin., PMID:32959257
Characterization of the UK anthrax vaccine and human immunogenicity., PMID:32897798
Bacillus subtilis spore vaccines displaying protective antigen induce functional antibodies and protective potency., PMID:32723323
Repeat Dose Toxicity Study of the AV7909 Anthrax Vaccine Candidate in Juvenile Rats., PMID:32691648
Immunogenicity of Non-Living Anthrax Vaccine Candidates in Cattle and Protective Efficacy of Immune Sera in A/J Mouse Model Compared to the Sterne Live Spore Vaccine., PMID:32664259
Two approaches for the stabilization of Bacillus anthracis recombinant protective antigen., PMID:32614657
Structural Integrity of the Alveolar-Capillary Barrier in Cynomolgus Monkeys Challenged with Fully Virulent and Toxin-Deficient Strains of Bacillus anthracis., PMID:32598882
Serological evidence for human exposure to Bacillus cereus biovar anthracis in the villages around Taï National Park, Côte d'Ivoire., PMID:32407387
For research use only. Not for human or drug use.
